Pandora wrote: Quattro74 wrote: He he Vestor,
Yeah this couod be one of those where it is better to sell it instead of licensing. I mean the sheer volume of NA Lung cancer patients.....
vestor111 wrote: Ok but how would RPCCC get to use it? License or open market sales of the compound through. normal sales channels? Naturally, I prefer the former. Would the latter open the flood gates?
This situation is both an opportunity as well as a puzzle for the company on how to proceed. They may know full well how they want things to unfold but have yet to open the Kimono. For all we know, discussions over this may be months in the making.
Things may not be as they seem, which makes it very intriguing.
But no matter what, it is great news.
How's this for the scam called Big Pharma?
From the GlobalTV news tonight:
B.C. parents fighting to raise millions for three-month-old daughter’s treatment
The family later learned 3 month old Lucy had been born without the SMN1 gene and was eventually diagnosed with spinal muscular atrophy, also known as SMA, which results in the loss of muscle movement.
However, the drug, called
Zolgensma, has only been approved by the U.S. Food and Drug Administration so far. But the trouble is, the drug costs $3 million.
AveXis,Inc., of Bannockburn, Ill., is the company that developed Zolgensma. The company is owned by drug giant Novartis.
The federal Food and Drug Administration has approved a gene therapy for a rare childhood disorder that is now the most expensive drug on the market. It costs $2.125 million U.S. per patient. There are currently around 700 patients eligible for the treatment, according to Novartis, and roughly 30 babies are born each month with the disease.
Novartis set the price at $2.125 million but offers insurers the ability to pay $425,000 a year for five years. This price tag makes Zolgensma the most expensive drug ever approved.
But for those patients lucky enough to get it, it appears it can save their lives with a one-time treatment.